Background: Pharmacological treatment of depression is currently led by the trial and error principle mainly because of lack of reliable biomarkers. Earlier fi ndings suggest that baseline alpha power and asymmetry could diff erentiate between responders and non-responders to specifi c antidepressants. Aim: The current study investigated quantitative electroencephalographic (QEEG) measures before and early in treatment as potential response predictors to various antidepressants in a naturalistic sample of depressed patients. We were aiming at developing markers for early prediction of treatment response based on diff erent QEEG measures. Materials and methods: EEG data from 25 depressed subjects were acquired at baseline and after one week of treatment. Mean and total alpha powers were calculated at eight electrode sites F3, F4, C3, C4, P3, P4, O1, O2. Response to treatment was defi ned as 50% decrease in MADRS score at week 4. Results: Mean P3 alpha predicted response with sensitivity and specifi city of 80%, positive and negative predictive values of 92.31% and 71.43%, respectively. The combined model of response prediction using mean baseline P3 alpha and mean week 1 C4 alpha values correctly identifi ed 80% of the cases with sensitivity of 84.62%, and specifi city of 71.43%. Conclusions: Simple QEEG measures (alpha power) acquired before initiation of antidepressant treatment could be useful in outcome prediction with an overall accuracy of about 80%. These fi ndings add to the growing body of evidence that alpha power might be developed as a reliable biomarker for the prediction of antidepressant response.
Depression is recognized as one of the most common and disabling psychiatric disorders. In addition to the suffering of the affected individuals and their families, there is a huge social and economic burden in terms of increased health-care costs, decreased productivity and absenteeism. 1 Due to lack of reliable biomarkers, current pharmacological treatment of depression is led mainly by the trial and error principle. Research in this area has been focused on examining several types of potential predictors such as early clinical improvement 2 , genetic markers 3 , different electroencephalographic measures 4 , and neuroimaging-derived markers. 5, 6 The potential of several quantitative electroencephalographic (QEEG) measures for the prediction of antidepressant response has been investigated in the last few decades. [7] [8] [9] The earliest studies found increased alpha power in responders compared to non-responders 10, 11 as well as greater alpha over the right compared to the left occipital sites. 12 Although some authors researching the predictive potential of the theta frequency band showed that higher absolute theta was associated with better response 13 , the majority of the studies found lower relative theta power in the groups of responders. 11, 14, 15 In several other QEEG studies, there was no pretreatment difference in alpha and theta powers between responders and non-responders to various antidepressants. [16] [17] [18] [19] [20] However, after the fi rst week of treatment, a difference in a measure called cordance emerged between the two groups of patients. Those that were eventually (after 4 weeks) categorized as responders showed a decrease in theta cordance, something that was not seen in the group of the non-responders. 18 Most of the alpha power studies were either placebo-controlled or open label on tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs), while some of the latest cordance studies implemented a naturalistic design and were thus closer to the clinical reality.
AIM
Based on these latest fi ndings, the aim of our study was to investigate quantitative electroencephalography as a potential treatment-predictor in a naturalistic sample of patients with major depression before and during the early stages (on day 7) of their treatment with various antidepressants. We were aiming at developing markers for early prediction of treatment response based on different QEEG measures.
MATERIALS AND METHODS

SUBJECTS
A total of 29 patients with major depressive disorder were recruited in the study. All patients fulfi lled the DSM-IV-TR criteria for this diagnosis, which was confi rmed using the Mini-International Neuropsychiatric Interview. 21 Subjects scoring more than 20 on the Montgomery-Åsberg Depression Rating Scale (MADRS) and more than 4 on the Clinical Global Impression-Severity (CGI-S) were included in the study. Patients not included in the study were those who had an unstable medical condition or a neurological disorder (e.g. epilepsy, head trauma with loss of consciousness), high suicidal risk (Clinical Global Impression-Suicidality -CGI-SS>2 and/or score on the 10 th item of MADRS>2), current psychiatric comorbidity, alcohol or substance abuse, electroconvulsive therapy (within 3 months before enrollment). A written informed consent was obtained from all subjects and the study protocol was reviewed and approved by the University's Ethics Committee. Three subjects dropped out after the fi rst visit and one did not come for the last one thus bringing the number of patients in the fi nal dataset down to 25. Clinical response was defi ned as change in MADRS score from baseline to week 4 by at least 50%, and remission as total MADRS score below 12 at week 4.
EXPERIMENTAL PROCEDURE
The study started with a wash-out period of at least 1 day followed by a four week antidepressant treatment. The prescription of the particular antidepressants was left to the attending psychiatrist taking into account the subject's history, clinical status and general treatment guidelines ( Table 1) . Continuation of stable doses of benzodiazepines was allowed for those subjects who used them before the study. Patients were rated on MADRS, CGI-S and CGI-SS and fi lled out self-assessment scales on depression (Beck Depression Inventory -BDI) at study enrollment, on days 0, 7, and 28 of treatment.
EEG data were recorded before (baseline) and after one week of treatment with Neuron Spectrum 5 EEG amplifi er (Neurosoft, Ivanovo, Russia) and a 19-channel electrode cap (Electro-Cap International, Eaten, Ohio, USA) using the 10/20 international electrode placement system. The EEG recordings were done in a quiet room with the patient in a comfortable seating position (with neck support), eyes closed in a maximally alerted state. The recording sessions were 20 minutes long with a sampling rate of 500 Hz. Low-and high-pass fi lters were applied to the data at 0.5 and 35 Hz, respectively. After visually inspecting the records for artifacts and periods of drowsiness or sleep, the best 30 sec. of vigilance were selected for further processing. Spectral analysis was performed by Fast-Fourier Transform (FFT) in the following frequency bands: delta (0.5-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), beta (12) (13) (14) (15) (16) (17) (18) (19) (20) . For each subject the mean and total alpha powers (in μV²), the alpha asymmetry (in %), the mean and total theta power (in μV²) and the theta asymmetry (in %) were calculated at eight electrode sites (F3, F4, C3, C4, P3, P4, O1, O2) using the Neurosoft ω software v 1.6.4.3.
In each frequency band the mean power is calculated by averaging all amplitudes taken from the respective part of the power spectrum. The total power is calculated in a similar way but the amplitudes are summed instead. The percentage of asymmetry is defi ned as the power difference between the left and right electrodes divided by the higher of the two values or 
STATISTICAL METHODS AND DATA ANALYSIS
Because of the small sample size, nonparametric statistical tests were used to perform the within group (Wilcoxon Sign Rank Test) and between group (Mann-Whitney U test, Fisher's exact test) analyses and the regression and correlation analyses (Spearman's Rho). The signifi cance level was set at 0.05 and all tests were two-sided. The software used for the statistical analysis was SPSS version 17 (IBM SPSS Statistics).
RESULTS
DEMOGRAPHIC CHARACTERISTICS AND CLINICAL MEASURES
A total of 25 subjects -9 men and 16 women (median age 56 years, Interquartile range (IQR) 49-63 years) were included in the analysis. After 4 weeks of treatment 14 of them were classifi ed as responders (MADRS decrease ≥50%) and 11 as non-responders. There was no signifi cant difference in their baseline characteristics except for the duration of the current depressive episode which was longer in non-responders (Table 1) . BASELINE QEEG PARAMETERS There were statistically signifi cant differences between responders and non-responders in the total alpha averaged for all electrode sites, as well as in the mean and total alpha power at F3 and P3 sites with the responders showing greater baseline values ( Table 2 ). The differences in the alpha asymmetry were not statistically signifi cant. There were no differences between the groups regarding the theta power and asymmetry at baseline.
between the groups (Table 1) . The infl uence of this factor was not statistically signifi cant (p=0.088 for F3 alpha and p=0.061 for P3 alpha).
WEEK 1 QEEG PARAMETERS
After one week of treatment the responders had higher mean and total alpha power at C3 and C4 than the non-responders (Table 3 ). There were no signifi cant differences between the two groups in alpha asymmetry, theta power and theta asymmetry Logistic regression was applied to study the predictive value of baseline F3 and P3 mean alpha power and similar values were acquired for sensitivity -80% (CI 51.91-95.67%) for F3 and 85.71% (CI 57.19-98.22%) for P3, specifi city -80% (CI 28.36-99.49%) for F3, 83.33% (CI 35.88-99.58%) for P3, positive predictive value (PPV) 92.31% (CI 63.97-99.81%) for both F3 and P3 and negative predictive value (NPV) 57.14 % (CI 18.41-90.10%) for F3 and 71.43% (CI 29.04-96.33%) for P3. Receiver operating characteristic (ROC) analysis of the predictive value of baseline mean P3 alpha gave an area under the curve (AUC) of 0.791 (Fig. 1) . Choosing a cut-off value of 2.68 gives a sensitivity of 76.9% and specifi city of 85.7%. Testing the mean F3 alpha power at baseline generates no higher AUC. In all analyses the duration of the current episode was added in order to be excluded as a confounding factor since it showed a signifi cant difference at week 1. Changes in the mean and total alpha and theta and the asymmetry were not signifi cantly different between responders and non-responders. The C3 and C4 mean alpha powers at week 1 were capable of differentiating responders from non-responders with a sensitivity of 85.71% (CI 59.19-98.22%) and 84.62% (CI 54.55-98.08%), respectively and specifi city of 83.33% (CI 35.88-99.58%) and 71.43 % (CI 29.04-96.33%) for C3 and C4, respectively. The duration of the current episode was not a signifi cant confounding factor.
By means of logistic regression, the association between the treatment response and the QEEG parameters at baseline and at week 1 was investigated while controlling for the duration of the current episode. The combined model of response prediction based on baseline mean P3 alpha and mean C4 alpha power at week 1 was statistically signifi cant χ 2(2) = 11.41, p <0.05. It explained 59.9% of the variance (Nagelkerke R 2 ) and correctly identifi ed 80% of the cases. The sensitivity of the test was 84.62% (CI 54.55-98.08%), and the specifi city -71.43 % (CI 29.04-96.33%).
DISCUSSION
To the best of our knowledge, this is the fi rst study to use QEEG alpha measures for the prediction of treatment response in a naturalistic sample of depressed patients. Our results demonstrate that before initiation of treatment the patients that were ultimately classifi ed as responders had greater total alpha power (across all electrodes) and mean alpha power in the frontal and parietal left sites (F3 and P3) as compared to the non-responders. After the fi rst week of treatment this difference was no longer statistically signifi cant but there emerged a difference at the central electrode sites (C3 and C4) where the responders showed again greater alpha power. The specifi c alpha measures showed substantial predictive capacity with overall accuracy around 80%. These fi ndings and their signifi cance are discussed below.
There is growing evidence that links resting EEG alpha with the so called Default Mode Network (DMN) that is activated during rest and deactivated during execution of tasks in functional magnetic resonance imaging (fMRI) studies. 22 The DMN has been linked to self-referential processes and is found to be mostly hyperactivated in depressed patients although some authors report the opposite pattern and yet other studies demonstrate both hypo-and hyperactivation of different structures within the network. 23 Depressed subjects appear to have higher alpha power compared to healthy controls 24 and some of the fi rst studies investigating the relation between EEG measures and treatment outcome 10, 11 found that responders had greater alpha compared to non-responders, which is generally in agreement with our results although this difference was more prominent at the occipital sites in the fi rst study and at the frontal sites in the second. In addition, our fi ndings on pretreatment alpha are consistent with some newer studies 12 , where responders to fl uoxetine had a tendency to demonstrate higher alpha power that did not reach statistical signifi cance (p=0.06) although they had signifi cantly more pronounced alpha asymmetry. Using different techniques for EEG analysis, Tenke et al. 25 reported higher alpha power in responders to SSRIs and SNRIs but found no difference in asymmetry. It is worth noting that based on previous results, most of the recent studies have focused only on posterior sites. Furthermore there are substantial differences in the EEG acquisition parameters (such as number of electrodes, montages) and subsequent analysis (absolute or relative power, current source density, independent component analysis) that could account for some of the inconsistencies of the fi ndings.
Our results after the fi rst week of treatment cannot be readily compared to other studies since most of them investigated the subjects for the second time at the end of the trial e.g. after several weeks of treatment. Studies that used the same design as ours with EEG recordings early in the treatment (on day 7) focused on a complex measure of absolute and relative theta power called cordance 26 and did not report on alpha measures.
The prediction of the treatment response based on the alpha measures before and after the fi rst week of antidepressant treatment in our study showed similar values for sensitivity and specifi city (around 80-85%) as did the combined model of prediction based on both pretreatment and week 1 alpha measures. This is to suggest that in further investigations baseline EEG might be suffi cient for the development of potential response markers.
There are confl icting results about the signifi cance, and more accurately, the direction of change in relative theta power in responders and non-responders. Most of the studies 11, 14, 15 demonstrated that relative theta power was lower in responders compared to non-responders. More recently, Iosifescu et al. 27 found that the relative theta power was lower in responders to SSRI or venlafaxine. Contrary to their results, Spronk et al. 13 reported that better treatment response of 25 depressed patients treated with SSRI and SNRI was associated with higher absolute theta power. In the present study no difference in theta power or asymmetry was found.
Limitations of this study are imposed by the small sample size and the lack of placebo controlled group. Because of the latter, we cannot overrule the possibility that some of the results are related to placebo response. The naturalistic design has its weak and strong sides. It does not allow us to control for the type of medication but at the same time is much closer to the clinical reality, which could facilitate the implementation of alpha power as an early predictor of response to treatment.
CONCLUSIONS
Our results suggest that simple QEEG measures (alpha power) acquired before initiation of treatment with various antidepressants could be useful in predicting the outcome in a clinical sample of patients with major depressive disorder. The test shows a reasonable predictive value with an overall accuracy of about 80%.
The fi ndings of this study add to the growing body of evidence that alpha power might be developed as a reliable biomarker for the prediction of antidepressant response in patients with major depression. Larger studies are needed in order to establish the reliability of this potential biomarker.
